List of bibliographic references
Number of relevant bibliographic references: 24.
[20-40] [
0 - 20][
0 - 24]
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 12 | Humans |
| 10 | Adult |
| 10 | Arthritis, Rheumatoid (drug therapy) |
| 10 | Female |
| 10 | Male |
| 10 | Middle Aged |
| 9 | Aged |
| 7 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 5 | Antirheumatic Agents (adverse effects) |
| 4 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 4 | Antirheumatic Agents (therapeutic use) |
| 4 | Chronic |
| 4 | Immunomodulator |
| 4 | Rheumatoid arthritis |
| 4 | Rheumatology |
| 4 | Risk Factors |
| 4 | Treatment Outcome |
| 3 | Antibodies, Monoclonal, Humanized |
| 3 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 3 | Drug Therapy, Combination |
| 3 | France (epidemiology) |
| 3 | Prospective Studies |
| 3 | Registries |
| 3 | Severity of Illness Index |
| 3 | Tocilizumab |
| 2 | Abatacept (adverse effects) |
| 2 | Antibodies, Monoclonal (therapeutic use) |
| 2 | Antirheumatic Agents (administration & dosage) |
| 2 | Arthritis, Rheumatoid (diagnosis) |
| 2 | Biological Factors (therapeutic use) |
| 2 | Cohort Studies |
| 2 | Drug Resistance |
| 2 | Follow-Up Studies |
| 2 | Incidence |
| 2 | Infusions, Intravenous |
| 2 | Peptides, Cyclic (immunology) |
| 2 | Rituximab (adverse effects) |
| 2 | Tumor Necrosis Factor Inhibitors (therapeutic use) |
| 2 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
| 2 | Young Adult |
| 2 | rheumatoid arthritis |
| 1 | |
| 1 | Abatacept |
| 1 | Abatacept (administration & dosage) |
| 1 | Abatacept (therapeutic use) |
| 1 | Adiponectin (metabolism) |
| 1 | Aged, 80 and over |
| 1 | Amyloid A amyloidosis |
| 1 | Amyloidosis (drug therapy) |
| 1 | Amyloidosis (pathology) |
| 1 | Anaphylaxis |
| 1 | Anaphylaxis (chemically induced) |
| 1 | Anaphylaxis (epidemiology) |
| 1 | Anti-Tumor Necrosis Factor-alpha |
| 1 | Antibodies |
| 1 | Antibodies, Monoclonal (adverse effects) |
| 1 | Antirheumatic Agents |
| 1 | Antirheumatic agent |
| 1 | Apolipoprotein A-I (drug effects) |
| 1 | Apolipoprotein B-100 (drug effects) |
| 1 | Arthritis |
| 1 | Arthritis, Rheumatoid (blood) |
| 1 | Arthritis, Rheumatoid (complications) |
| 1 | Arthritis, Rheumatoid (epidemiology) |
| 1 | Arthritis, Rheumatoid (immunology) |
| 1 | Arthritis, Rheumatoid (metabolism) |
| 1 | Autoantibodies (blood) |
| 1 | Bayes Theorem |
| 1 | Biomarkers (blood) |
| 1 | Biotherapy |
| 1 | Cardiovascular Diseases (blood) |
| 1 | Certolizumab Pegol |
| 1 | Certolizumab pegol |
| 1 | Clinical management |
| 1 | Comparative study |
| 1 | Contraindications |
| 1 | Cyclic |
| 1 | Cytokine |
| 1 | Double-Blind Method |
| 1 | Drug Eruptions |
| 1 | Drug Eruptions (epidemiology) |
| 1 | Drug Eruptions (etiology) |
| 1 | Drug Monitoring (methods) |
| 1 | Drug Monitoring (statistics & numerical data) |
| 1 | Drug Therapy, Combination (methods) |
| 1 | Drug Therapy, Combination (statistics & numerical data) |
| 1 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
| 1 | Drug-Related Side Effects and Adverse Reactions (etiology) |
| 1 | Evidence-Based Medicine |
| 1 | Glucocorticoids (adverse effects) |
| 1 | Glucocorticoids (therapeutic use) |
| 1 | Human |
| 1 | Humanized |
| 1 | Hypertension |
| 1 | Hypertension (chemically induced) |
| 1 | Hypertension (epidemiology) |
| 1 | Immunoglobulin Fab Fragments (therapeutic use) |
| 1 | Immunosuppressive agent |
| 1 | Infusions |
| 1 | Insulin Resistance (physiology) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Jean Sibilia"
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i \
-Sk "Jean Sibilia" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= France
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Jean Sibilia
}}
| This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021 |  |
